open access

Vol 8, No 4 (2006)
Published online: 2007-01-19
Get Citation

Secondary prophylaxis of deep venous thromboembolism. When is the application of low-molecular-weight heparins advisable? Review of the literature

Dawid Hadasik, Jacek Kostecki, Maciej Zaniewski
Chirurgia Polska 2006;8(4):275-284.

open access

Vol 8, No 4 (2006)
Published online: 2007-01-19

Abstract

Deep vein thrombosis of the lower limbs is a frequent therapeutic problem, and additionally makes hemodynamic functioning of the venous system worse for a long time. Treatment and primary prophylaxis does not arouse controversies today. The secondary prevention of the deep vein thombosis lets one effectively counteract post-thrombotic syndrome. Low molecular weight heparins have nearly completely substituted nowadays unfracted heparins in primary prophylaxis. In secondary prophylaxis it is generally accepted to administer oral anticoagulants, but there are numerous contraindications for administered oral anticoagulants. Also many side effects are caused by these medicines. In this paper, the authors wanted to answer the following question: in which patients does the administration of LMWH in secondary prophylaxis bring benefits? They analysed over 50 articles and found some conclusions. There are many advantages for pregnant patients and those suffering from a cancer who should be treated with low-molecular-weight heparins. Many authors have noticed that LMWH and oral anticoagulants have a similar efficacy and a comparable amount of serious haemorrhagic complications. Except for the groups of patients who need long-term prophylaxis, the physician together with the patient should decide on what method of treatment to choose.

Abstract

Deep vein thrombosis of the lower limbs is a frequent therapeutic problem, and additionally makes hemodynamic functioning of the venous system worse for a long time. Treatment and primary prophylaxis does not arouse controversies today. The secondary prevention of the deep vein thombosis lets one effectively counteract post-thrombotic syndrome. Low molecular weight heparins have nearly completely substituted nowadays unfracted heparins in primary prophylaxis. In secondary prophylaxis it is generally accepted to administer oral anticoagulants, but there are numerous contraindications for administered oral anticoagulants. Also many side effects are caused by these medicines. In this paper, the authors wanted to answer the following question: in which patients does the administration of LMWH in secondary prophylaxis bring benefits? They analysed over 50 articles and found some conclusions. There are many advantages for pregnant patients and those suffering from a cancer who should be treated with low-molecular-weight heparins. Many authors have noticed that LMWH and oral anticoagulants have a similar efficacy and a comparable amount of serious haemorrhagic complications. Except for the groups of patients who need long-term prophylaxis, the physician together with the patient should decide on what method of treatment to choose.
Get Citation

Keywords

deep vein thrombosis; secondary prophylaxis; oral anticoagulants; low molecular weight heparin

About this article
Title

Secondary prophylaxis of deep venous thromboembolism. When is the application of low-molecular-weight heparins advisable? Review of the literature

Journal

Chirurgia Polska (Polish Surgery)

Issue

Vol 8, No 4 (2006)

Pages

275-284

Published online

2007-01-19

Bibliographic record

Chirurgia Polska 2006;8(4):275-284.

Keywords

deep vein thrombosis
secondary prophylaxis
oral anticoagulants
low molecular weight heparin

Authors

Dawid Hadasik
Jacek Kostecki
Maciej Zaniewski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaBy "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl